舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状的疗效及安全性分析  

The efficacy and safety analysis of Shugan Jieyu capsule combined with clomipramine in the treatment of liver disease related somatic symptoms

作　　者：张玉波[1] 孙燕[1] 李佳桂[2] 祖庆余 赵静[1] 张彬辉 刘红静[1] 陈立敏[1] ZHANG Yu-bo;SUN Yan;LI Jia-gui;ZU Qing-yu;ZHAO Jing;ZHANG Bin-hui;LIU Hong-jing;CHEN Li-min(Department of Gastroenterology, Zhuozhou Hospital, Hebei Province, Zhuozhou 07275 0,China;Department of Critical Care Medicine,Zhuozhou Hospital, Hebei Province,Zhuozhou 072750,China)

机构地区：[1]涿州市医院消化内科,河北涿州072750 [2]涿州市医院重症医学科,河北涿州072750

出　　处：《中国中西医结合消化杂志》2019年第8期600-603,共4页Chinese Journal of Integrated Traditional and Western Medicine on Digestion

基　　金：保定市科技计划项目(No:17ZF118)

摘　　要：[目的]研究舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状的疗效及安全性分析。[方法]选取我院收治的肝病相关躯体化症状患者90例,随机分为2组,每组各45例。对照组患者口服盐酸氯米帕明片,1片/次,2次/d,治疗组在对照组基础上每日给予舒肝解郁胶囊,2粒/次,2次/d,早晚各1次,2组患者持续治疗6周。对比2组临床疗效、HAMD评分、HAMA评分和TESS评分。[结果]经过治疗后,2组治疗有效率进行比较,治疗组较高(P<0.05);2组患者HAMD评分和HAMA评分均显著低于治疗前(P<0.05);并且治疗组降低程度较大(P<0.05);2组患者TESS评分差异无统计学意义。[结论]采用舒肝解郁胶囊联合氯米帕明用于治疗肝病相关躯体化症状,具有较好的临床疗效,能够改善患者HAMD评分和HAMA评分,安全性较高,值得在临床推广应用。[Objective]To investigate the efficacy and safety of shugan jieyu capsule combined with clomiphene in the treatment of liver disease-related somatic symptoms.[Methods]90 patients with liver disease-related somatic symptoms admitted to our hospital were randomly divided into two groups of 45 patients each.Patients in the control group were given clomipramine hydrochloride tablets orally,1 tablet per time and 2 times per day.On the basis of the control group,patients in the treatment group were given shugan jieyu capsules every day,2 tablets per time and 2 times per day,once in the morning and once in the evening.Patients in the two groups received continuous treatment for 6 weeks.Clinical efficacy,HAMD score,HAMA score and TESS score were compared between the two groups.[Results]After treatment,the effective rates of the two groups were compared,and were higher in the treatment group(P <0.05).HAMD score and HAMA score were significantly lower in the two groups than before treatment(P<0.05).In addition,the degree of reduction was greater in the treatment group(P<0.05).There was no significant difference in TESS score between treatment group and control group(P>0.05).[Conclusion]Shugan jieyu capsule combined with clomiphene for the treatment of liver disease-related somatic symptoms has a good clinical effect,which can improve the patient’s HAMD score and HAMA score,and has high safety.It is worthy of clinical application.

关 键 词：舒肝解郁胶囊 氯米帕明 肝病相关躯体化症状 安全性分析 

分 类 号：R575[医药卫生—消化系统]